Designing small molecules for therapeutic success: A contemporary perspective by Maurer, Tristan S., Edwards, Martin, Hepworth, David, Verhoest, Patrick, Allerton, Charlotte M.N.

Get full text

Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route by Blagg, Julian, Allerton, Charlotte M.N., Batchelor, David V.J., Baxter, Andrew D., Burring, Denise J., Carr, Christopher L., Cook, Andrew S., Nichols, Carly L., Phipps, Joanne, Sanderson, Vivienne G., Verrier, Hugh, Wong, Stephen

Get full text

A Novel Series of Potent and Selective PDE5 Inhibitors with Potential for High and Dose-Independent Oral Bioavailability by Allerton, Charlotte M. N, Barber, Christopher G, Beaumont, Kevin C, Brown, David G, Cole, Susan M, Ellis, David, Lane, Charlotte A. L, Maw, Graham N, Mount, Natalie M, Rawson, David J, Robinson, Colin M, Street, Stephen D. A, Summerhill, Nicholas W

Get full text

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance by Zhu, Yuao, Yurgelonis, Irina, Noell, Stephen, Yang, Qingyi, Guan, Shunjie, Li, Zhenghui, Hao, Li, Rothan, Hussin, Rai, Devendra K, McMonagle, Patricia, Baniecki, Mary Lynn, Greasley, Samantha E, Plotnikova, Olga, Lee, Jonathan, Nicki, Jennifer A, Ferre, RoseAnn, Byrnes, Laura J, Liu, Wei, Craig, Timothy K, Steppan, Claire M, Liberator, Paul, Soares, Holly D, Allerton, Charlotte M N, Anderson, Annaliesa S, Cardin, Rhonda D

Get full text

Design and synthesis of pyridazinone-based 5-HT2C agonists by ALLERTON, Charlotte M. N, ANDREWS, Mark D, WARD, Robin, WATSON, Lesa, BLAGG, Julian, ELLIS, David, EVRARD, Edel, GREEN, Martin P, LIU, Kevin K.-C, MCMURRAY, Gordon, RALPH, Michael, SANDERSON, Vivienne

Get full text

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 by Owen, Dafydd R, Allerton, Charlotte M N, Anderson, Annaliesa S, Aschenbrenner, Lisa, Avery, Melissa, Berritt, Simon, Boras, Britton, Cardin, Rhonda D, Carlo, Anthony, Coffman, Karen J, Dantonio, Alyssa, Li, Di, Eng, Heather, Ferre, RoseAnn, Gajiwala, Ketan S, Gibson, Scott A, Greasley, Samantha E, Hurst, Brett L, Kadar, Eugene P, Kalgutkar, Amit S, Lee, Jack C, Lee, Jisun, Liu, Wei, Mason, Stephen W, Noell, Stephen, Novak, Jonathan J, Obach, R Scott, Ogilvie, Kevin, Patel, Nandini C, Pettersson, Martin, Rai, Devendra K, Reese, Matthew R, Sammons, Matthew F, Sathish, Jean G, Singh, Ravi Shankar P, Steppan, Claire M, Stewart, Al E, Tuttle, Jamison B, Updyke, Lawrence, Verhoest, Patrick R, Wei, Liuqing, Yang, Qingyi, Zhu, Yuao

Get full text

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2c agonists by ANDREWS, Mark D, GREEN, Martin P, WATSON, Lesa, ALLERTON, Charlotte M. N, BATCHELOR, David V, BLAGG, Julian, BROWN, Alan D, GORDON, David W, MCMURRAY, Gordon, MILLNS, Daniel J, NICHOLS, Carly L

Get full text

Design, synthesis and biological activity of β-carboline-based type-5 phosphodiesterase inhibitors by Maw, Graham N., Allerton, Charlotte M.N., Gbekor, Eugene, Million, William A.

Get full text

A Second-Generation Oral SARS-CoV‑2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 by Allerton, Charlotte M. N., Arcari, Joel T., Aschenbrenner, Lisa M., Avery, Melissa, Bechle, Bruce M., Behzadi, Mohammad Amin, Boras, Britton, Buzon, Leanne M., Cardin, Rhonda D., Catlin, Natasha R., Carlo, Anthony A., Coffman, Karen J., Dantonio, Alyssa, Di, Li, Eng, Heather, Farley, Kathleen A., Ferre, Rose Ann, Gernhardt, Steven S., Gibson, Scott A., Greasley, Samantha E., Greenfield, Siennah R., Hurst, Brett L., Kalgutkar, Amit S., Kimoto, Emi, Lanyon, Lorraine F., Lovett, Gabrielle H., Lian, Yajing, Liu, Wei, Martínez Alsina, Luis A., Noell, Stephen, Obach, R. Scott, Owen, Dafydd R., Patel, Nandini C., Rai, Devendra K., Reese, Matthew R., Rothan, Hussin A., Sakata, Sylvie, Sammons, Matthew F., Sathish, Jean G., Sharma, Raman, Steppan, Claire M., Tuttle, Jamison B., Verhoest, Patrick R., Wei, Liuqing, Yang, Qingyi, Yurgelonis, Irina, Zhu, Yuao

Get full text

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 by Owen, Dafydd R, Allerton, Charlotte M N, Anderson, Annaliesa S, Aschenbrenner, Lisa, Avery, Melissa, Berritt, Simon, Boras, Britton, Cardin, Rhonda D, Carlo, Anthony, Coffman, Karen J, Dantonio, Alyssa, Di, Li, Eng, Heather, Ferre, RoseAnn, Gajiwala, Ketan S, Gibson, Scott A, Greasley, Samantha E, Hurst, Brett L, Kadar, Eugene P, Kalgutkar, Amit S, Lee, Jack C, Lee, Jisun, Liu, Wei, Mason, Stephen W, Noell, Stephen, Novak, Jonathan J, Obach, R Scott, Ogilvie, Kevin, Patel, Nandini C, Pettersson, Martin, Rai, Devendra K, Reese, Matthew R, Sammons, Matthew F, Sathish, Jean G, Singh, Ravi Shankar P, Steppan, Claire M, Stewart, Al E, Tuttle, Jamison B, Updyke, Lawrence, Verhoest, Patrick R, Wei, Liuqing, Yang, Qingyi, Zhu, Yuao

Get full text

Design and synthesis of pyridazinone-based 5-HT sub(2C) agonists by Allerton, Charlotte MN, Andrews, Mark D, Blagg, Julian, Ellis, David, Evrard, Edel, Green, Martin P, Liu, Kevin K-C, McMurray, Gordon, Ralph, Michael, Sanderson, Vivienne, Ward, Robin, Watson, Lesa

Get full text

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT sub(2C) agonists by Andrews, Mark D, Green, Martin P, Allerton, Charlotte MN, Batchelor, David V, Blagg, Julian, Brown, Alan D, Gordon, David W, McMurray, Gordon, Millns, Daniel J, Nichols, Carly L, Watson, Lesa

Get full text

Design and synthesis of pyridazinone-based 5-HT(2C) agonists by Allerton, Charlotte M N, Andrews, Mark D, Blagg, Julian, Ellis, David, Evrard, Edel, Green, Martin P, Liu, Kevin K-C, McMurray, Gordon, Ralph, Michael, Sanderson, Vivienne, Ward, Robin, Watson, Lesa

Get full text

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists by Andrews, Mark D, Green, Martin P, Allerton, Charlotte M N, Batchelor, David V, Blagg, Julian, Brown, Alan D, Gordon, David W, McMurray, Gordon, Millns, Daniel J, Nichols, Carly L, Watson, Lesa

Get full text

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 by Boras, Britton, Jones, Rhys M., Anson, Brandon J., Arenson, Dan, Aschenbrenner, Lisa, Bakowski, Malina A., Beutler, Nathan, Binder, Joseph, Chen, Emily, Eng, Heather, Hammond, Holly, Hammond, Jennifer, Haupt, Robert E., Hoffman, Robert, Kadar, Eugene P., Kania, Rob, Kimoto, Emi, Kirkpatrick, Melanie G., Lanyon, Lorraine, Lendy, Emma K., Lillis, Jonathan R., Logue, James, Luthra, Suman A., Ma, Chunlong, Mason, Stephen W., McGrath, Marisa E., Noell, Stephen, Obach, R. Scott, O’ Brien, Matthew N., O’Connor, Rebecca, Ogilvie, Kevin, Owen, Dafydd, Pettersson, Martin, Reese, Matthew R., Rogers, Thomas F., Rosales, Romel, Rossulek, Michelle I., Sathish, Jean G., Shirai, Norimitsu, Steppan, Claire, Ticehurst, Martyn, Updyke, Lawrence W., Weston, Stuart, Zhu, Yuao, White, Kris M., García-Sastre, Adolfo, Wang, Jun, Chatterjee, Arnab K., Mesecar, Andrew D., Frieman, Matthew B., Anderson, Annaliesa S., Allerton, Charlotte

Get full text

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial by Hiller, Louise, Vallier, Anne-Laure, McAdam, Karen, Hughes-Davies, Luke, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Raynes, Kerry, Higgins, Helen B, Plummer, Chris, Mansi, Janine, Mahler–Araujo, Betania, Abraham, Jean E, Caldas, Carlos, McCabe, Christopher, Miles, David, Wardley, Andrew M, Cameron, David A, Agarwal, Roshan, Algurafi, Hafiz, Archer, Caroline, Armstrong, Anne, Bale, Catherine, Barraclough, Lisa, Barthakur, Urmila, Bedi, Carolyn, Benstead, Kim, Bloomfield, David, Bowen, Rebecca, Bradley, Chris, Brown, Jane, Butt, Mohammad, Churn, Mark, Cleator, Susan, Cliff, Joanne, Crellin, Perric, Daly, Margaret, De Silva-Minor, Shiroma, Dhadda, Amandeep, Din, Omar, Down, Sue, Earl, Helena, Eaton, David, Eichholz, Andrew, Epurescu, Daniel, Goh, Chee, Goodman, Andrew, Grieve, Robert, Hadaki, Maher, Harper-Wynne, Catherine, Harries, Mark, Hayward, Larry, Humphreys, Alison, Innes, Helen, Jafri, Mariam, Jegannathen, Apurna, Kelleher, Muireann, Kristeleit, Hartmut, Lee, Daniela, Lupton, Susan, MacGregor, Carol, Malik, Zafar, Mansi, Janine, Marshall, Jennifer, McAdam, Karen, McGolick, Trevor, Mehra, Rakesh, Miles, David, Mithal, Natasha, Moss, Charlotte, Moss, Aian, Nelmes, Daniel, Neville-Webbe, Helen, Newby, Jacqueline, O'Reilly, Susan, Ostler, Peter, Persic, Mojca, Pettit, Laura, Raj, Sanjay, Raja, Fharat, Rea, Daniel, Reed, Catherine, Rigg, Anne, Roe, Helen, Shah, Nihal, Simmonds, Peter, Sims, Eliot, Smith, Sarah, Storey, Nicola, Taylor, Wendy, Tipples, Karen, Vaidya, Jayant, Varughese, Mohini, Walji, Nawaz, Woodings, Pamela, Wright, Kathryn, Yahya, Sundus

Get full text

Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort studyResearch in context by Hamish J.C. McAuley, Rachael A. Evans, Charlotte E. Bolton, Christopher E. Brightling, James D. Chalmers, Annemarie B. Docherty, Omer Elneima, Paul L. Greenhaff, Ayushman Gupta, Victoria C. Harris, Ewen M. Harrison, Ling-Pei Ho, Alex Horsley, Linzy Houchen-Wolloff, Caroline J. Jolley, Olivia C. Leavy, Nazir I. Lone, William D-C Man, Michael Marks, Dhruv Parekh, Krisnah Poinasamy, Jennifer K. Quint, Betty Raman, Matthew Richardson, Ruth M. Saunders, Marco Sereno, Aarti Shikotra, Amisha Singapuri, Sally J. Singh, Michael Steiner, Ai Lyn Tan, Louise V. Wain, Carly Welch, Julie Whitney, Miles D. Witham, Janet Lord, Neil J. Greening, K. Abel, H. Adamali, D. Adeloye, O. Adeyemi, R. Adrego, L.A. Aguilar Jimenez, S. Ahmad, N. Ahmad Haider, R. Ahmed, N. Ahwireng, M. Ainsworth, B. Al-Sheklly, A. Alamoudi, M. Ali, M. Aljaroof, A.M. All, L. Allan, R.J. Allen, L. Allerton, L. Allsop, P. Almeida, D. Altmann, M. Alvarez Corral, S. Amoils, D. Anderson, C. Antoniades, G. Arbane, A. Arias, C. Armour, L. Armstrong, N. Armstrong, D. Arnold, H. Arnold, A. Ashish, A. Ashworth, M. Ashworth, S. Aslani, H. Assefa-Kebede, C. Atkin, P. Atkin, R. Aul, H. Aung, L. Austin, C. Avram, A. Ayoub, M. Babores, R. Baggott, J. Bagshaw, D. Baguley, L. Bailey, J.K. Baillie, S. Bain, M. Bakali, M. Bakau, E. Baldry, D. Baldwin, M. Baldwin, C. Ballard, A. Banerjee, B. Bang, R.E. Barker, L. Barman, S. Barratt

Get full text

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19 by Boras, Britton, Jones, Rhys M, Anson, Brandon J, Arenson, Dan, Aschenbrenner, Lisa, Bakowski, Malina A, Beutler, Nathan, Binder, Joseph, Chen, Emily, Eng, Heather, Hammond, Holly, Hammond, Jennifer, Haupt, Robert E, Hoffman, Robert, Kadar, Eugene P, Kania, Rob, Kimoto, Emi, Kirkpatrick, Melanie G, Lanyon, Lorraine, Lendy, Emma K, Lillis, Jonathan R, Logue, James, Luthra, Suman A, Ma, Chunlong, Mason, Stephen W, Mcgrath, Marisa E, Noell, Stephen, Obach, R Scott, Matthew N O’brien, Rebecca O’connor, Ogilvie, Kevin, Owen, Dafydd, Pettersson, Martin, Reese, Matthew R, Rogers, Thomas F, Rossulek, Michelle I, Sathish, Jean G, Shirai, Norimitsu, Steppan, Claire, Ticehurst, Martyn, Updyke, Lawrence W, Weston, Stuart, Zhu, Yuao, Wang, Jun, Chatterjee, Arnab K, Mesecar, Andrew D, Frieman, Matthew B, Anderson, Annaliesa S, Allerton, Charlotte

Request full text